DMRA on Nasdaq
Damora Therapeutics, Inc.
American pharmaceutical preparations company based in Boston.
$18.32 down 0.11 (0.60%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 18, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $26.9M | $6.4M |
| Acquired in-process research and development | $174.3M | $4.4M |
| General and administrative | $9.7M | $10.5M |
| Restructuring costs | $0 | $968.0K |
| Total operating expenses | $210.9M | $22.3M |
| Loss from operations | -$210.9M | -$22.3M |
| Interest income, net | $1.2M | $844.0K |
| Foreign exchange transaction gain (loss), net | -$84.0K | $18.0K |
| Total other income, net | $1.1M | $862.0K |
| Loss before income tax expense | -$209.8M | -$21.4M |
| Income tax expense | -$50.0K | -$41.0K |
| Net loss | -$209.8M | -$21.4M |
| Net loss per share, basic, common stock | $3.98 | -$18.53 |
| Net loss per share, diluted, common stock | $3.98 | -$18.53 |
| Weighted-average number of shares used in computing net loss per common share, basic | 1.4M shares | 1.2M shares |
| Weighted-average number of shares used in computing net loss per common share, diluted | 1.4M shares | 1.2M shares |
| Currency translation gain (loss) | $705.0K | -$283.0K |
| Other comprehensive income (loss), net of tax | $705.0K | -$283.0K |
| Total comprehensive loss | -$209.1M | -$21.7M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $257.6M | $14.2M | |
| Prepaid expenses and other current assets | $2.8M | $2.7M | |
| Total current assets | $260.4M | $16.8M | |
| Operating lease right-of-use asset | $68.0K | $73.0K | |
| Equipment, net | $36.0K | $57.0K | |
| Other assets, noncurrent | $0 | $163.0K | |
| Total assets | $260.5M | $17.1M | |
| Accounts payable | $444.0K | $377.0K | |
| Accrued expenses and other current liabilities | $2.4M | $820.0K | |
| Total current liabilities | $20.1M | $1.2M | |
| Operating lease liabilities, noncurrent | $53.0K | $61.0K | |
| Other liabilities, noncurrent | $28.0K | $43.0K | |
| Total liabilities | $20.1M | $1.3M | |
| Mezzanine equity, Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024; 159 shares issued and outstanding as of December 31, 2025 and 161 shares issued or outstanding as of December 31, 2024 | $1.3M | $1.4M | |
| Additional paid-in capital | $310.7M | $291.9M | |
| Accumulated deficit | -$487.4M | -$277.5M | |
| Accumulated other comprehensive income | $802.0K | $97.0K | |
| Total stockholders equity | $240.4M | $15.8M | $32.3M |
| Total liabilities and stockholders equity | $260.5M | $17.1M | |
| Mezzanine equity, Preferred stock, par value | $0.00 | $0.00 | |
| Mezzanine equity, Preferred stock, authorized | 10.0M shares | 10.0M shares | |
| Mezzanine equity, Preferred stock, issued | 159 shares | 161 shares | |
| Mezzanine equity, Preferred stock, outstanding | 159 shares | 161 shares | |
| Preferred stock, shares authorized | 10.0M shares | ||
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, authorized | 500.0M shares | 500.0M shares | |
| Common stock, issued | 1.6M shares | 1.3M shares | |
| Common stock, outstanding | 1.6M shares | 1.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $257.6M | $14.2M | |
| Prepaid expenses and other current assets | $2.8M | $2.7M | |
| Total current assets | $260.4M | $16.8M | |
| Operating lease right-of-use asset | $68.0K | $73.0K | |
| Equipment, net | $36.0K | $57.0K | |
| Other assets, noncurrent | $0 | $163.0K | |
| Total assets | $260.5M | $17.1M | |
| Accounts payable | $444.0K | $377.0K | |
| Accrued expenses and other current liabilities | $2.4M | $820.0K | |
| Total current liabilities | $20.1M | $1.2M | |
| Operating lease liabilities, noncurrent | $53.0K | $61.0K | |
| Other liabilities, noncurrent | $28.0K | $43.0K | |
| Total liabilities | $20.1M | $1.3M | |
| Mezzanine equity, Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024; 159 shares issued and outstanding as of December 31, 2025 and 161 shares issued or outstanding as of December 31, 2024 | $1.3M | $1.4M | |
| Additional paid-in capital | $310.7M | $291.9M | |
| Accumulated deficit | -$487.4M | -$277.5M | |
| Accumulated other comprehensive income | $802.0K | $97.0K | |
| Total stockholders equity | $240.4M | $15.8M | $32.3M |
| Total liabilities and stockholders equity | $260.5M | $17.1M | |
| Mezzanine equity, Preferred stock, par value | $0.00 | $0.00 | |
| Mezzanine equity, Preferred stock, authorized | 10.0M shares | 10.0M shares | |
| Mezzanine equity, Preferred stock, issued | 159 shares | 161 shares | |
| Mezzanine equity, Preferred stock, outstanding | 159 shares | 161 shares | |
| Preferred stock, shares authorized | 10.0M shares | ||
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, authorized | 500.0M shares | 500.0M shares | |
| Common stock, issued | 1.6M shares | 1.3M shares | |
| Common stock, outstanding | 1.6M shares | 1.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$209.8M | -$21.4M |
| Depreciation of equipment | $22.0K | $21.0K |
| Stock-based compensation | $998.0K | $3.2M |
| Issuance of common stock in connection with vesting of restricted stock units | $39.0K | $93.0K |
| Issuance of preferred and common stock in connection with an Asset Purchase Agreement | $1.9M | |
| In-process research and development costs in connection with Damora Asset Acquisition | $174.3M | |
| Issuance of Paramora Warrant, net of cost assumed in Damora Asset Acquisition | $9.4M | |
| Amortization of premiums and discounts on marketable securities | $70.0K | |
| Amortization of right of use lease asset | $12.0K | $160.0K |
| Accretion of lease liability | $6.0K | $10.0K |
| Prepaid expenses and other current assets | -$138.0K | $954.0K |
| Other assets, noncurrent | $166.0K | $970.0K |
| Accounts payable | $51.0K | -$1.3M |
| Accrued expenses and other current liabilities | $1.1M | -$3.1M |
| Related party accounts payable and other current liabilities | $17.2M | |
| Operating lease liabilities | -$20.0K | -$170.0K |
| Other liabilities, noncurrent | -$15.0K | $43.0K |
| Net cash used in operating activities | -$6.7M | -$18.6M |
| Damora Asset Acquisition costs, net of cash assumed | -$17.4M | |
| Proceeds from sale of marketable securities | $11.7M | |
| Net cash (used in) provided by investing activities | -$17.4M | $11.7M |
| Proceeds from issuance of preferred stock in connection with private placement, net of issuance costs | $266.8M | |
| Proceeds from issuance of common stock in connection with stock option exercise | $33.0K | |
| Net cash provided by financing activities | $266.8M | |
| Net increase (decrease) in cash and cash equivalents | $242.7M | -$7.0M |
| Effect of exchange rate changes on cash and cash equivalents | $705.0K | -$317.0K |
| Cash paid for taxes | $5.0K | |
| Fair value of the Series B Preferred Stock issued in connection with the Damora Asset Acquisition | $152.7M | |
| Operating lease liability arising from obtaining right-of-use assets | $75.0K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Damora Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
2025
- Chief executive officerJennifer Jarrett Sep 28, 2026 to now12
- Chief executive officerHans T. Schambye Oct 28, 2020 to Sep 28, 202613
- PresidentJennifer Jarrett Sep 28, 2026 to now12
- Chief financial officerLori Firmani Aug 16, 2024 to now14
- Chief financial officerJonathan Freve Oct 28, 2020 to Jan 5, 202415
- Chief operating officerSherwin Sattarzadeh Jan 26, 2026 to now16
- Chief operating officerAnders Pedersen Oct 28, 2020 to Jan 5, 202317
Board members and other officers (24)
- Chief Medical OfficerL. Becker Hewes Jan 7, 2026 to now18
- OfficerJennifer Jarrett Apr 1, 2026 to now19
- SVP, FinanceBrian Burkavage May 8, 2026 to now20
- EVP Strategy and CBOMatthew Kronmiller Oct 11, 2024 to Jan 7, 202521
- Chief Business OfficerStephanie Oestreich Jan 5, 2022 to Jan 5, 202322
- Chief Medical OfficerBertil Lindmark Oct 28, 2020 to Jan 5, 202323
- Board memberCameron Turtle Mar 25, 2026 to now24
- Board memberMichael Landsittel Mar 25, 2026 to now25
- Board memberJennifer Jarrett Apr 1, 2026 to now19
- Board memberAndrew Cheng Aug 13, 2026 to now26
- Board memberChristopher W. Cain Nov 17, 2025 to now27
- Board memberJulianne Bruno Nov 17, 2025 to now28
- Board memberPeter Evan Harwin Nov 17, 2025 to now29
- Board memberAmy B. Wechsler Oct 15, 2024 to now30
- Board memberAnne Prener Jan 8, 2021 to now31
- Board memberAmit Munshi Oct 28, 2020 to now32
- Board memberCarl Goldfischer Oct 28, 2020 to now33
- Board memberChau Quang Khuong Oct 28, 2020 to Jun 15, 202334
- Board memberHans T. Schambye Oct 28, 2020 to now13
- Board memberIsrael Gp L.p. Orbimed Ii. Oct 28, 2020 to Nov 4, 202035
- Board memberSoren Moller Oct 28, 2020 to Oct 28, 202036
- Board memberStephan Christgau Oct 28, 2020 to Nov 4, 202037
- Board memberJayson Donald Alexander Dallas Nov 23, 2020 to now38
- General counselGarrett Winslow May 11, 2021 to now39
Former names
Timeline
Filings
273 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 34 major events, 96 insider forms, 36 large holders, 1 private raises, 86 other. The latest 20:
- Sep 28, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 13, 20263 EDGAR
- Aug 12, 2026EFFECT EDGAR
- Aug 10, 2026S-8 POS EDGAR
- Aug 10, 2026S-8 POS EDGAR
- Aug 10, 2026POSASR EDGAR
- Aug 10, 2026S-8 POS EDGAR
- Aug 10, 2026S-8 POS EDGAR
- Aug 10, 2026S-8 POS EDGAR
- Aug 10, 2026S-8 POS EDGAR
- Aug 10, 2026S-8 POS EDGAR
- Aug 10, 2026S-8 POS EDGAR
- Aug 10, 2026POS AM EDGAR
- Aug 10, 20268-A12B/A EDGAR
- Aug 10, 202610-Q EDGAR
- Aug 6, 2026144 EDGAR
- Jul 28, 2026SCHEDULE 13G EDGAR
- Jul 20, 20268-K EDGAR
- Jul 7, 20264 EDGAR
The 273 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last three years, summarized. The full record is on SEC EDGAR.
Insider trades and holders
Large holders
Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 36 such filings since October 2021, the latest 10:
- Jul 28, 2026SCHEDULE 13G
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G/A
- May 15, 2026SCHEDULE 13G
- Apr 23, 2026SCHEDULE 13G/A
- Apr 23, 2026SCHEDULE 13G/A
- Mar 6, 2026SCHEDULE 13G/A
- Feb 17, 2026SCHEDULE 13G
- Feb 17, 2026SCHEDULE 13G
- Feb 11, 2026SCHEDULE 13D/A
From Forms 4 and Schedules 13D and 13G filed with the SEC.
Money raised
Private offerings the company reported to the SEC on Form D.
- Nov 12, 2025Raised $285 million in a private offering of equity Form D: 48 investors so far Form D
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceDMRA quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19SEC EDGARJennifer Jarrett, Officer
- 20SEC EDGARBrian Burkavage, SVP, Finance
- 21
- 22
- 23
- 24SEC EDGARCameron Turtle, Board member
- 25SEC EDGARMichael Landsittel, Board member
- 26SEC EDGARAndrew Cheng, Board member
- 27SEC EDGARChristopher W. Cain, Board member
- 28SEC EDGARJulianne Bruno, Board member
- 29SEC EDGARPeter Evan Harwin, Board member
- 30SEC EDGARAmy B. Wechsler, Board member
- 31SEC EDGARAnne Prener, Board member
- 32SEC EDGARAmit Munshi, Board member
- 33SEC EDGARCarl Goldfischer, Board member
- 34SEC EDGARChau Quang Khuong, Board member
- 35
- 36SEC EDGARSoren Moller, Board member
- 37SEC EDGARStephan Christgau, Board member
- 38
- 39SEC EDGARGarrett Winslow, General counsel